Literature summary extracted from

Digumarti, R.; Sinha, S.; Nirni, S.S.; Patil, S.G.; Pedapenki, R.M.
Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia an Indian experience (2014), Indian J. Cancer, 51, 180-183 .

Application

EC Number	Application	Comment	Organism
1.7.3.3	medicine	treatment of patients with high risk for tumor lysis syndrome with 0.2 mg/kg intravenously over 30 min, daily, for 4 days leads to 75.3% reduction in plasma uric acid at 4 h as compared to baseline. Recombinant rasburicase that is indigenously developed is effective for prevention and management of hyperuricemia in patients who are at high risk of developing tumor lysis syndrome	Aspergillus flavus

Cloned(Commentary)

EC Number	Cloned (Comment)	Organism
1.7.3.3	expression in Saccharomyces cerevisiae	Aspergillus flavus

Organism

EC Number	Organism	UniProt	Comment	Textmining
1.7.3.3	Aspergillus flavus	-	-	-

Synonyms

EC Number	Synonyms	Comment	Organism
1.7.3.3	Rasburicase	-	Aspergillus flavus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)